HDL Cholesterol Clinical Trial
Official title:
Effects of Tibolone and PPARĪ±-agonist on HDL Metabolism in Postmenopausal Women
Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%.
This study aims to study the effects of fenofibrate on HDL and subfractions in women taking
tibolone.
Tibolone decreases plasma concentrations of HDL cholesterol and HDL-apoA1 and pre-beta HDL,
consistent with a pro-atherogenic effect. The mechanism of tibolone on HDL cholesterol has
been suggested to result from an acceleration of the catabolism of HDL by stimulation of
hepatic lipase with no effect on cellular cholesterol efflux.
PPAR-a agonists, in particular fenofibrate, improve HDL metabolism by increasing the
expression and hepatic secretion of HDL apoAI and apoAII.
We hypothesise that fenofibrate will rectify the perturbations on HDL metabolism wrought by
tibolone.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
| Active, not recruiting |
NCT00238004 -
The Low HDL On Six Weeks Statin Therapy (LOW) Study
|
Phase 4 | |
| Completed |
NCT00389896 -
A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)
|
Phase 3 | |
| Recruiting |
NCT00736463 -
Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)
|
Phase 4 | |
| Completed |
NCT00765284 -
Effect of Niaspan on Cholesterol in Men
|
N/A |